U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C6H14N2.C2O4.Pt
Molecular Weight 397.2859
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXALIPLATIN

SMILES

C1CC[C@]([H])([C@@]([H])(C1)N)N.C(=O)(C(=O)[O-])[O-].[Pt+2]

InChI

InChIKey=ZROHGHOFXNOHSO-BNTLRKBRSA-L
InChI=1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1

HIDE SMILES / InChI

Molecular Formula C6H14N2
Molecular Weight 114.189
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Pt
Molecular Weight 195.0778
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C2O4
Molecular Weight 88.0191
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Oxaliplatin (brand name Eloxatin), a new generation of platinum derivatives discovered by Prof Kidani in 1976 at Nagoya University in Japan, was licensed-in and developed by Debiopharm. Eloxatin is typically administered in combination with fluorouracil and leucovorin for the adjuvant treatment of stage III colon cancer and for the treatment of advanced carcinoma of the colon or rectum. Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo 1,2-diaminocyclohexane (DACH) platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.

CNS Activity

Curator's Comment:: Known to be CNS non-penetrant in nonhuman primates. Human data not available

Originator

Curator's Comment:: Prof Kidani in 1976 at Nagoya University in Japan

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2311221
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ELOXATIN

Approved Use

Oxaliplatin, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: •adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. •treatment of advanced colorectal cancer. Oxaliplatin injection is a platinum-based drug used in combination with infusional 5-fluorouracil/leucovorin, which is indicated for: •adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. (1) •treatment of advanced colorectal cancer. (1)

Launch Date

1028851200000
Primary
ELOXATIN

Approved Use

Oxaliplatin, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: •adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. •treatment of advanced colorectal cancer. Oxaliplatin injection is a platinum-based drug used in combination with infusional 5-fluorouracil/leucovorin, which is indicated for: •adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. (1) •treatment of advanced colorectal cancer. (1)

Launch Date

1028851200000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.66 μg/mL
130 mg/m² 1 times / 3 weeks steady-state, intravenous
dose: 130 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
OXALIPLATIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
205.75 μg × h/mL
130 mg/m² 1 times / 3 weeks steady-state, intravenous
dose: 130 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
OXALIPLATIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
42.84 h
130 mg/m² 1 times / 3 weeks steady-state, intravenous
dose: 130 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
OXALIPLATIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
PLATINUM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
130 mg/m2 single, intravenous
Dose: 130 mg/m2
Route: intravenous
Route: single
Dose: 130 mg/m2
Sources:
unhealthy, 56 years
Health Status: unhealthy
Age Group: 56 years
Sex: F
Sources:
Disc. AE: Hypersensitivity reaction...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity reaction (1 patient)
Sources:
135 mg/m2 1 times / 4 weeks multiple, intravenous
Dose: 135 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 135 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, 57 years (range: 26-81 years)
Health Status: unhealthy
Age Group: 57 years (range: 26-81 years)
Sex: M+F
Sources:
DLT: Neurotoxicity...
Dose limiting toxicities:
Neurotoxicity (50%)
Sources:
150 mg/m2 1 times / 4 weeks multiple, intravenous
Dose: 150 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, 57 years (range: 26-81 years)
Health Status: unhealthy
Age Group: 57 years (range: 26-81 years)
Sex: M+F
Sources:
DLT: Neurotoxicity...
Dose limiting toxicities:
Neurotoxicity (64%)
Sources:
175 mg/m2 1 times / 4 weeks multiple, intravenous
Dose: 175 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 175 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, 57 years (range: 26-81 years)
Health Status: unhealthy
Age Group: 57 years (range: 26-81 years)
Sex: M+F
Sources:
DLT: Neurotoxicity...
Dose limiting toxicities:
Neurotoxicity (71%)
Sources:
200 mg/m2 1 times / 4 weeks multiple, intravenous
Dose: 200 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, 57 years (range: 26-81 years)
Health Status: unhealthy
Age Group: 57 years (range: 26-81 years)
Sex: M+F
Sources:
DLT: Neurotoxicity...
Dose limiting toxicities:
Neurotoxicity (100%)
Sources:
55 mg/m2 multiple, intravenous
Dose: 55 mg/m2
Route: intravenous
Route: multiple
Dose: 55 mg/m2
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: F
Sources:
Disc. AE: Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (1 patient)
Sources:
150 mg/m2 1 times / 3 weeks single, intravenous
Dose: 150 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: single
Dose: 150 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 60 years (range: 33-75 years)
Health Status: unhealthy
Age Group: 60 years (range: 33-75 years)
Sex: M+F
Sources:
Disc. AE: Diarrhoea...
AEs leading to
discontinuation/dose reduction:
Diarrhoea (grade 3, 1 patient)
Sources:
725 mg/m2 single, intravenous
Dose: 725 mg/m2
Route: intravenous
Route: single
Dose: 725 mg/m2
Sources:
unhealthy, 60 years (range: 33-75 years)
Health Status: unhealthy
Age Group: 60 years (range: 33-75 years)
Sex: M+F
Sources:
Disc. AE: Peripheral sensory neuropathy...
AEs leading to
discontinuation/dose reduction:
Peripheral sensory neuropathy (1 patient)
Sources:
900 mg/m2 single, intravenous
Dose: 900 mg/m2
Route: intravenous
Route: single
Dose: 900 mg/m2
Sources:
unhealthy, 60 years (range: 33-75 years)
Health Status: unhealthy
Age Group: 60 years (range: 33-75 years)
Sex: M+F
Sources:
Disc. AE: Peripheral sensory neuropathy...
AEs leading to
discontinuation/dose reduction:
Peripheral sensory neuropathy (1 patient)
Sources:
925 mg/m2 single, intravenous
Dose: 925 mg/m2
Route: intravenous
Route: single
Dose: 925 mg/m2
Sources:
unhealthy, 60 years (range: 33-75 years)
Health Status: unhealthy
Age Group: 60 years (range: 33-75 years)
Sex: M+F
Sources:
Disc. AE: Peripheral sensory neuropathy...
AEs leading to
discontinuation/dose reduction:
Peripheral sensory neuropathy (1 patient)
Sources:
130 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 130 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 130 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 64 years
Health Status: unhealthy
Age Group: 64 years
Sex: M
Sources:
Disc. AE: Lhermitte's sign...
AEs leading to
discontinuation/dose reduction:
Lhermitte's sign (1 patient)
Sources:
85 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 85 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 85 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
Other AEs: Anaphylactic reaction...
AEs

AEs

AESignificanceDosePopulation
Hypersensitivity reaction 1 patient
Disc. AE
130 mg/m2 single, intravenous
Dose: 130 mg/m2
Route: intravenous
Route: single
Dose: 130 mg/m2
Sources:
unhealthy, 56 years
Health Status: unhealthy
Age Group: 56 years
Sex: F
Sources:
Neurotoxicity 50%
DLT
135 mg/m2 1 times / 4 weeks multiple, intravenous
Dose: 135 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 135 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, 57 years (range: 26-81 years)
Health Status: unhealthy
Age Group: 57 years (range: 26-81 years)
Sex: M+F
Sources:
Neurotoxicity 64%
DLT
150 mg/m2 1 times / 4 weeks multiple, intravenous
Dose: 150 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, 57 years (range: 26-81 years)
Health Status: unhealthy
Age Group: 57 years (range: 26-81 years)
Sex: M+F
Sources:
Neurotoxicity 71%
DLT
175 mg/m2 1 times / 4 weeks multiple, intravenous
Dose: 175 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 175 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, 57 years (range: 26-81 years)
Health Status: unhealthy
Age Group: 57 years (range: 26-81 years)
Sex: M+F
Sources:
Neurotoxicity 100%
DLT
200 mg/m2 1 times / 4 weeks multiple, intravenous
Dose: 200 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, 57 years (range: 26-81 years)
Health Status: unhealthy
Age Group: 57 years (range: 26-81 years)
Sex: M+F
Sources:
Thrombocytopenia 1 patient
Disc. AE
55 mg/m2 multiple, intravenous
Dose: 55 mg/m2
Route: intravenous
Route: multiple
Dose: 55 mg/m2
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: F
Sources:
Diarrhoea grade 3, 1 patient
Disc. AE
150 mg/m2 1 times / 3 weeks single, intravenous
Dose: 150 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: single
Dose: 150 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 60 years (range: 33-75 years)
Health Status: unhealthy
Age Group: 60 years (range: 33-75 years)
Sex: M+F
Sources:
Peripheral sensory neuropathy 1 patient
Disc. AE
725 mg/m2 single, intravenous
Dose: 725 mg/m2
Route: intravenous
Route: single
Dose: 725 mg/m2
Sources:
unhealthy, 60 years (range: 33-75 years)
Health Status: unhealthy
Age Group: 60 years (range: 33-75 years)
Sex: M+F
Sources:
Peripheral sensory neuropathy 1 patient
Disc. AE
900 mg/m2 single, intravenous
Dose: 900 mg/m2
Route: intravenous
Route: single
Dose: 900 mg/m2
Sources:
unhealthy, 60 years (range: 33-75 years)
Health Status: unhealthy
Age Group: 60 years (range: 33-75 years)
Sex: M+F
Sources:
Peripheral sensory neuropathy 1 patient
Disc. AE
925 mg/m2 single, intravenous
Dose: 925 mg/m2
Route: intravenous
Route: single
Dose: 925 mg/m2
Sources:
unhealthy, 60 years (range: 33-75 years)
Health Status: unhealthy
Age Group: 60 years (range: 33-75 years)
Sex: M+F
Sources:
Lhermitte's sign 1 patient
Disc. AE
130 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 130 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 130 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 64 years
Health Status: unhealthy
Age Group: 64 years
Sex: M
Sources:
Anaphylactic reaction
85 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 85 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 85 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
PubMed

PubMed

TitleDatePubMed
Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases.
2000 Sep-Oct
Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
2005 Feb 15
Structural basis for the sequence-dependent effects of platinum-DNA adducts.
2009 May
Recognition of platinum-DNA damage by poly(ADP-ribose) polymerase-1.
2010 Jul 27
Patents

Patents

Sample Use Guides

Adjuvant treatment in patients with stage III colon cancer is recommended for a total of 6 months, i.e., 12 cycles, every 2 weeks, according to the dose schedule described below for previously treated patients with advanced colorectal cancer.
Route of Administration: Intravenous
The anti-proliferative effects of oxaliplatin in human HT29 and NMG64/84 colon and COLO-357 MIA PaCa-2 and PMH2/89 pancreatic cancer cell lines and in fresh liver metastases from patients with colorectal and pancreatic cancer were investigated using the human tumor colony forming assay. Oxaliplatin significantly inhibited the colony formation in all cell lines in a concentration- and time-dependent manner. All liver tumors displayed a significant concentration-dependent inhibition of colony formation after exposure to oxaliplatin for 2 hours. The IC50 of oxaliplatin of 9 of the 10 tumors was < 10 micrograms/ml.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:05:09 UTC 2021
Edited
by admin
on Fri Jun 25 21:05:09 UTC 2021
Record UNII
04ZR38536J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXALIPLATIN
EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
OXALIPLATIN [JAN]
Common Name English
OXALIPLATIN [MART.]
Common Name English
OXALIPLATIN [USP MONOGRAPH]
Common Name English
PLATINUM, ((1R,2R)-1,2-CYCLOHEXANEDIAMINE-.KAPPA.N,.KAPPA.N')(ETHANEDIOATO(2-)-.KAPPA.O1,.KAPPA.O2)-, (SP-4-2)-
Common Name English
JM-83
Code English
OXALIPLATIN [VANDF]
Common Name English
OXALIPLATIN [WHO-DD]
Common Name English
OXALIPLATIN [ORANGE BOOK]
Common Name English
OXALIPLATIN [EP MONOGRAPH]
Common Name English
SR-96669
Code English
OXALIPLATIN [INN]
Common Name English
MBP-426 (LIPOSOMAL OXALIPLATIN)
Code English
NSC-266046
Code English
OXALIPLATIN [USP-RS]
Common Name English
XALIPLATIN
Brand Name English
(SP-4-2-(1R-TRANS))-(1,2-CYCLOHEXANEDIAMINE-N,N')(ETHANEDIOATO(2-)-O,O')PLATINUM
Common Name English
OXALIPLATIN [MI]
Common Name English
ELOXATIN
Brand Name English
OXALIPLATIN [USAN]
Common Name English
L-OHP
Code English
RP-54780
Code English
OXALIPLATIN [EP]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 561716
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
WHO-VATC QL01XA03
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
WHO-ATC L01XA03
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
FDA ORPHAN DRUG 560816
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
FDA ORPHAN DRUG 605617
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
LIVERTOX 718
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
NCI_THESAURUS C1450
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
NDF-RT N0000175073
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
NDF-RT N0000175413
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
FDA ORPHAN DRUG 69492
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
Code System Code Type Description
INN
6012
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY
MESH
C030110
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY
DRUG BANK
DB00526
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY
FDA UNII
04ZR38536J
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY
IUPHAR
7433
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY
DRUG CENTRAL
4210
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY
CAS
61825-94-3
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY
MERCK INDEX
M8281
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY Merck Index
EPA CompTox
61825-94-3
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY
USP_CATALOG
1481204
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY USP-RS
EVMPD
SUB09490MIG
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY
RXCUI
32592
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY RxNorm
LACTMED
Oxaliplatin
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY
ChEMBL
CHEMBL414804
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY
WIKIPEDIA
OXALIPLATIN
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY
NCI_THESAURUS
C1181
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY
PUBCHEM
9887054
Created by admin on Fri Jun 25 21:05:09 UTC 2021 , Edited by admin on Fri Jun 25 21:05:09 UTC 2021
PRIMARY
Related Record Type Details
LABELED -> NON-LABELED
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
TRANSPORTER -> SUBSTRATE
MAY BE RESPONSIBLE FOR THE ACTIVITY OF OXALIPLATIN AGAINST against colorectal tumors
MAJOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
TRANSPORTER -> SUBSTRATE
MAY BE RESPONSIBLE FOR THE ACTIVITY OF OXALIPLATIN AGAINST against colorectal tumors
MAJOR
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
limites not given
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY